Rationale and design of the DAPA-MI trial: Dapagliflozin in patients without diabetes mellitus with acute myocardial infarction-Reference-Cited by-同舟云学术

Rationale and design of the DAPA-MI trial: Dapagliflozin in patients without diabetes mellitus with acute myocardial infarction

Published:2023-12 Issue: Volume:266 Page:188-197
ISSN:0002-8703
Container-title:American Heart Journal
language:en
Short-container-title:American Heart Journal

Author:

James Stefan,Erlinge David,Storey Robert F.,McGuire Darren K.,de Belder Mark,Björkgren Ida,Johansson Peter A.,Langkilde Anna Maria,Ridderstråle Wilhelm,Parvaresh Rizi Ehsan,Deanfield John,Oldgren Jonas

Funder

AstraZeneca Mölndal

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference38 articles.

1. Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995-2014;Szummer;Eur Heart J,2017

2. Relations between implementation of new treatments and improved outcomes in patients with non-ST-elevation myocardial infarction during the last 20 years: experiences from SWEDEHEART registry 1995 to 2014;Szummer;Eur Heart J,2018

3. Cardiovascular disease in Europe 2015: epidemiological update;Townsend;Eur Heart J,2015

4. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes;Zinman;N Engl J Med,2015

5. Dapagliflozin and cardiovascular outcomes in type 2 diabetes;Wiviott;N Engl J Med,2019

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Use of cardiovascular registries in regulatory pathways: perspectives from the EU-MDR Cardiovascular Collaboratory;REC: interventional cardiology (English Edition);2024-09-13

2. Protocol for a randomized controlled trial of intensive blood pressure control on cardiovascular risk reduction in patients with atrial fibrillation: rationale and design of the CRAFT trial;American Heart Journal;2024-09

3. Patients’ experiences of clinical trial participation involving a product remotely assessing study drug adherence;Contemporary Clinical Trials Communications;2024-08

4. Empagliflozin to prevent progressive adverse remodelling after myocardial infarction (EMPRESS‐MI): rationale and design;ESC Heart Failure;2024-05-07

5. Sodium Glucose Co-Transporter 2 Inhibition Following Acute Myocardial Infarction;JACC: Heart Failure;2024-05